Exult Healthcare is now Anchor. Same team, same clinics.

Call (972) 369-4220

Psychiatry · Therapy · TMS · Spravato®

Advanced mental health care, for a brighter tomorrow.

Finding the right treatment can take time. We’re here to help you understand your options.

Why we exist

Mental health care in the United States is broken.

Gaps in care leave patients who genuinely want to get better stuck in a one-path trap that assumes a single solution can tackle everything.

Enter Anchor

Our clinicians zoom in on the problem and keep the whole context in view. Mental health struggles are often part of a larger story.

We ask: what is the medical history not yet telling us? And what is missing from the picture?

From FDA-cleared TMS to FDA-approved Spravato®, Anchor offers advanced treatment options alongside psychiatry and therapy.

Anchor brings psychiatry and therapy together with advanced treatments like TMS and Spravato®. This expands the options available to people who need something different.

  • Accepted insurance
  • Aetna
  • Anthem Blue Cross
  • Baylor Scott & White
  • BlueCross BlueShield
  • Cigna
  • Humana Behavioral Health
  • Magellan Health
  • Medicare
  • Optum
  • TRICARE
  • UHC
  • + 7 more

How it works

Start with what you’re experiencing.

You don’t need to know which treatment is right for you. We work that out together.

  1. 01

    Talk with our team

    Call us or send a request online. Tell us what you’re experiencing, in your own words.

  2. 02

    Meet your clinician

    Meet a psychiatrist or therapist in Sherman, in McKinney, or by telehealth. They work to understand your concerns and build a treatment plan with you.

  3. 03

    Begin treatment

    Start your plan with regular check-ins. As your needs change, your options change with them.

A clinician positions a TMS helmet for a patient.

What Anchor means

A steady point, not a fixed path.

Mental healthcare rarely follows a straight line. Finding what works can take time, adjustment, and sometimes more than one approach.

Anchor represents something steady within that process. A place patients can return to as their needs change, with the support and options to keep moving forward.

  • Board-certified psychiatrists and licensed therapists
  • Psychiatry, therapy, TMS, and Spravato® in one practice
  • Clinics in Sherman and McKinney, and telehealth in Texas
  • 10,000 patients
  • 30 modalities
  • 15 years
  • 2 locations

Research

The possibilities are expanding.

Decades of research have continued to broaden the ways clinicians can approach depression. Patients now have more options when traditional treatments haven’t been enough.

  1. 2008

    TMS reaches clinical practice

    The first TMS device for major depressive disorder received FDA authorization. Non-invasive magnetic brain stimulation became a clinical treatment option for certain patients with depression.

  2. 2013

    Deep TMS expands the field

    The FDA cleared BrainsWay’s Deep TMS system for depressive episodes in people with MDD who had not sufficiently improved with prior antidepressant medication.

  3. 2019

    Spravato® is FDA-approved

    The FDA approved Spravato® (esketamine) nasal spray, used with an oral antidepressant, for adults with treatment-resistant depression.

  4. 2023

    Evidence continues to grow

    A meta-analysis of 19 randomized, sham-controlled rTMS studies found higher response and remission rates than sham treatment. The ESCAPE-TRD trial reported 27.1% remission at eight weeks with esketamine nasal spray, compared with 17.6% with extended-release quetiapine.

  5. 2025

    Spravato® becomes a monotherapy option

    The FDA expanded the indication. Adults with treatment-resistant depression can now use Spravato® without an accompanying oral antidepressant.

2× more likely to respond

Across 19 randomized, double-blind, sham-controlled studies (854 participants for response), patients receiving rTMS were 2.25× as likely to achieve a treatment response as the comparison group. Across nine studies (551 participants), they were 2.78× as likely to achieve remission.

Vida RG, Sághy E, Bella R, et al. Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials. BMC Psychiatry. 2023;23:545.

Sources

  1. U.S. Food & Drug Administration. NeuroStar TMS System. K061053. Decision date: Oct. 7, 2008.
  2. U.S. Food & Drug Administration. BrainsWay Deep TMS System. 510(k) K122288. Decision date: Jan. 7, 2013.
  3. U.S. Food & Drug Administration. Spravato® (esketamine) nasal spray. NDA 211243. 2019.
  4. Vida RG, et al. BMC Psychiatry. 2023;23:545. doi:10.1186/s12888-023-05033-y.
  5. Reif A, et al. N Engl J Med. 2023;389:1298-1309. doi:10.1056/NEJMoa2304145.
  6. U.S. Food & Drug Administration. Spravato® (esketamine) Prescribing Information. NDA 211243. Current FDA labeling.

Our evolution

Built from one vision. Designed to grow.

Exult Healthcare began with Dr. Deepika Bhargava’s vision to bring mental health and addiction care together. As the practice has grown, its identity needs to grow with it.

Anchor carries that foundation forward while creating room for a broader team, expanding services, and new ways of delivering care.

  • Exult Healthcare→Anchor
  • Physician-led→Scalable
  • Founder-centered→Practice-wide
  • Established foundation→Room to grow
Dr. Deepika Bhargava
Dr. Deepika Bhargava, MD · Medical Director

Get started

Finding the right treatment can take time. We’re here to help you understand your options.

Mon-Fri: 9:00 AM – 6:00 PM · Sherman and McKinney, Texas